Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation’s unaudited Q3...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders...
OTC Markets Group Welcomes Antibe Therapeutics to OTCQX® PR Newswire NEW YORK, Sept. 15, 2014 NEW YORK, Sept. 15, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0.2156 | 0.2156 | 0.2156 | 0 | 0 | CS |
26 | -0.10905 | -33.5900200216 | 0.32465 | 0.3345 | 0.1113 | 43320 | 0.17097542 | CS |
52 | -0.131 | -37.7957299481 | 0.3466 | 0.8855 | 0.1113 | 25549 | 0.47870776 | CS |
156 | -0.7346 | -77.3100399916 | 0.9502 | 1.065 | 0.1113 | 16978 | 0.5391015 | CS |
260 | -0.06295 | -22.5991742955 | 0.27855 | 5.88 | 0.1113 | 83693 | 0.60515122 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.